Optibrium CEO to speak at Fusion’s 2017 drug discovery conference on supporting neglected diseases

Neglected diseases continue to cause significant morbidity and mortality in the developing world. Of 850 new therapeutic products approved between 2000 and 2011, onlyoptibr.png 4% (and only 1% of all approved NCEs) were indicated for neglected diseases, even though these diseases account for 11% of the global disease burden.

To help support the effort to address some of the world’s biggest health issues, Optibrium is providing access to its StarDrop software to support drug discovery projects as part of a global health programme focused on developing new treatments. The international consortium of academic and not-for-profit organisations includes Anacor, Broad Institute, Epichem, Infectious Disease Research Institute (IDRI), Medicines for Malaria Venture (MMV), Sandexis, TB Alliance, UNICAMP, University of California San Diego, University of Cape Town, University of Dundee and University of Liverpool.

Consortium partners are involved in projects to facilitate and speed up the development of therapies for the treatment of so-called “neglected” diseases such as leishmaniasis, sleeping sickness, Chagas disease, malaria, tuberculosis and paediatric HIV. StarDrop’s unique compound optimisation and design capabilities will help researchers to efficiently focus their efforts on researching candidate drugs with the best chance of success in becoming effective therapies in the treatment and prevention of these diseases.

Dr Matthew Segall, Optibrium’s CEO, commented, “We are very proud to support such an important effort to address some of the world’s biggest health issues. Drug development is enormously time consuming, expensive and high risk, due to the challenge of finding high quality candidate drugs with the right balance of efficacy and safety. By adopting StarDrop, consortium partners have access to a wide range of tools enabling their researchers to quickly target compounds with the highest chance of success and avoid missed opportunities.”

Join Dr Segall at the 3rd Drug Discovery Re-Invented conference to learn more about how StarDrop provides a wide range of tools that help researchers to quickly identify high quality chemistries and explore new strategies for further optimisation and to discuss the emerging role of BioTechs, Academics and not-for-profits in the battle against diseases.

The conference takes place in Cancun, Mexico between 21 – 24 February 2017 and is organised by Fusion Conferences. You can find out more information on the 3rd Drug Discovery Re-Invented conference at https://www.fusion-conferences.com/conference45.php.




Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s